Sells Ryoncil, a cell-based treatment for children with steroid-refractory acute graft-versus-host disease, and develops cell therapies for patients with cardiovascular, immune and spine conditions.
20-F for FY2026, filed Aug 27, 2026In December 2024, the FDA approved Mesoblast’s Ryoncil® for the treatment of pediatric SR-aGvHD in children 2 months and older. The Group…View ↗
Mesoblast's most significant contribution to sustainability lies in its core mission: expanding access to innovative treatments for…View ↗
We recognize that as a biotechnology company developing innovative, cell-based medicines, our stakeholders – including patients, HCPs…View ↗
Mesoblast earns from Ryoncil product sales and licensing deals: partners pay upfront fees, milestone payments when clinical, regulatory or commercial targets are met, and royalties on licensed-product sales. Payments are generally due in 30 to 60 days.
20-F for FY2026, filed Aug 27, 2026Revenues from contracts with customers comprise royalty and milestone revenue and revenue from product sales.View ↗
Royalty and milestone revenue generally includes non-refundable upfront license and collaboration fees; milestone payments, the receipt of…View ↗
(ii) Revenue from product salesView ↗
In December 2024, the FDA approved Mesoblast’s Ryoncil® for the treatment of pediatric SR-aGvHD in children 2 months and older. The Group…View ↗
$120.3M
20-F for FY2026, filed Aug 27, 2026
$120.3M ↗
Product sales flow through the U.S. distribution channel; pharmaceutical partners receive regional rights and handle development or commercialization in their markets.
20-F for FY2026, filed Aug 27, 2026The Group has credit risk exposure to customers in the U.S. distribution channel. As at June 30, 2026 and 2025, 98.0% and 89.3% of the…View ↗
In September 2019, the Group entered into a strategic partnership with Grünenthal for the development and commercialization in Europe and…View ↗
In July 2018, the Group entered into a strategic alliance with Tasly Pharmaceutical Group (“Tasly”) for the development, manufacture and…View ↗
No. It lost $57.5M in FY2026.
Growing. Revenue grew 11.8x in 4 years, from $10.2M in FY2022 to $120.3M in FY2026, about 85% a year.
Commercial product
The older report described remestemcel-L as awaiting U.S. approval for pediatric steroid-refractory acute graft-versus-host disease; the latest report says Ryoncil received approval and Mesoblast began commercializing it for that use.
20-F for FY2023, filed Aug 31, 2023 20-F for FY2026, filed Aug 27, 2026United States Food & Drug Administration (“FDA”) provided a complete response to the Biologics License Application (“BLA”) resubmission for…View ↗
Loading...